• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Lonza Expands PyroTec PRO for Endotoxin Testing

    FDA Accepts Airway Therapeutics’ IND for COVID Treatment

    Sanofi Invests in Cutting Edge Vax Production Site in Singapore

    Lilly Modifies Purchase Agreement with U.S. for COVID Therapies

    Sanofi Acquires Tidal Therapeutics
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Ascendia Pharmaceuticals Poised for Expansion

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lonza Expands PyroTec PRO for Endotoxin Testing

    FDA Accepts Airway Therapeutics’ IND for COVID Treatment

    Sanofi Invests in Cutting Edge Vax Production Site in Singapore

    Digitalization and the Future of Formulating in Modern R&D Labs

    Sanofi Acquires Tidal Therapeutics
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    PCI Pharma Services

    Syngene

    Reed-Lane

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Quotient Sciences

    Alcami

    PCI Pharma Services

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Pharma Beat

    Toward a Process-Centered Pharma

    Saying “No” to change is normal, but adopting true QbD practices could save the industry about 20-25% of its global revenue and allow pharma to add two to three billion patients to its customer base

    Girish Malhotra, EPCOT International06.03.14
    Not too long ago, a new three-letter acronym was introduced to an industry already full of them: QbD, an abbreviation for “Quality by Design.” The term states, succinctly, the fundamental goal and premise of any business: to deliver a quality product or service. Without this quality, chaos results, and it can have a serious impact on profits.

    Everything has to be done right the first time. If a second chance is needed to bring product in spec, profit will be lowered, as it might take many iterations to meet quality, and even these attempts may fail. Precise process sequencing is the key to any manufacturing business, whether we are making steel, alloys, gasoline, automobiles or plastics.

    Businesses achieving quality the first time did not give the processes or methods involved (product design, manufacture, process or execution sequence or whatever we want to name them) a name like QbD or any other three-letter acronym. They simply applied the fundamentals of math, chemistry and physics and common sense in manufacturing or service.

    So what about pharmaceuticals? Since QbD was introduced in the pharma hemisphere there has been significant discussion of what it is, what does it do, how and what to do. There has been a lot of optimism surrounding the term, which is noble. However, in the process, some have come to view QbD as a magic act that will cure all quality issues and comply with regulatory requirements.

    The sad reality is that the pharma industry, in the last 50 years, has not figured out how to apply the fundamentals of chemistry, physics and math (the same foundations of good practices that are being used in every manufacturing and service industry today) to API manufacturing and dose formulations, which, in totality, create processes that deliver quality products with little or no in-process tweaking.

    If we pick up any trade journal, attend any conference or read any newspaper article related to pharmaceuticals the emphasis is on new products that will cure diseases for a limited population covered by a healthcare [mutually subsidized] program. The focus is on sophisticated methods and procedures that will tell us the quality of the product. These methods do not tell us how to produce quality product. If the product does not meet the specifications, it is due to our lack of command of the process. We have to repeat the process steps and analyze the sample to see how close we are to the desired result. The process of repeated sampling and analysis will eventually let us produce a quality product. I call the whole process QbA “quality by aggravation/analysis” that will result in lower profits than what we could have had if we knew what we were doing.

    At times unnecessary investments are suggested in the name of regulatory compliance. If they do not give command of the process, do not improve asset utilization and repeated analysis is still necessary to check for quality, they should be carefully considered. I am not sure such investments have any return or value. They increase the cost of drugs. Patients willingly pay because no one knows or cares to know the real costs. Longevity is the driver. 

    I’m not saying this to criticize phama’s current practices but to spur discussion of what can change the landscape tomorrow. Imagine increasing profits while lowering the global healthcare costs and adding billions to their customer base. Other than pharmaceuticals, no other business has such an enviable opportunity. 

    Why Regulations are Needed
    Of course, some of you will respond that pharma must follow FDA regulations of some such thing.  But other industries have to comply with their respective regulations, but they seem to have adjusted well and are able to comply. This isn’t always the case with pharma.

    As consumers, would we drive a car if we knew that its brakes would have to be checked every time we wanted to use it? Or would we fly in a plane where the landing gear had to be replaced when parked at the departure gate? However, for drugs we might not have many choices. Even if we know that they are produced by inefficient methods or even could be adulterated, we need them, and we all want to live forever.

    FDA and other regulatory bodies are there to ensure products of repeatable and consistent approved quality are available. If the pharmaceutical industry could have the best practice at every step of the way that will produce consistent quality products, there may not be much need for regulatory bodies. However, having regulatory bodies is good as they keep rogue companies at bay.

    The underlying question is: What have pharma companies done to exceed regulations in their manufacturing practices? We might see published examples of energy conservation or complying with environmental regulations. We may never see many examples of an API being produced using continuous process instead of batch process, or improving the yield from 30% to 85% or improving equipment use time from 35% to 75% or reducing the batch cycle time from 168 hours to 30 hours. If we saw these examples they will suggest that has excellent command of the process and product quality. If ISO 55000 standards were to be applied to API manufacture and their formulations, my conjecture is that both operations would be at the bottom of the list.

    Pharma and the Current Model
    Regulations in any competitive environment are generally good for the customers as the products produced will be of the highest quality and best price. However, in a non-competitive environment, the customer is generally at a disadvantage, as is the case with patent protected pharmaceuticals. Regulations are a must in this environment. One would expect generic drugs, since they are off patent, to be significantly lower priced. They are, but not to the extent that they could be if economies of scale were applied. In either case the drugs are priced at highest level in a subsidized or pay from your pocket scenario. Generally the explanation of high prices is on costs associated with drug discovery even when everyone knows that the drug discovery and other business practices (raw materials to finished products) are known to be inefficient. Very little emphasis is placed on effort that could lower costs. As stated earlier drug discovery and their methods and devices are not part of this discussion.

    Pharma’s current business model is based on age-old practices of fragmented/multiple brand or generic manufacturing facilities. Generally the focus of the pharma companies, under the current regulatory guidelines, and “regulation centricity”, is to get the product to the market as fast as possible and it works for most of the companies. Patients absorb business inefficiencies. Extending life is more important than pointing to the inefficiencies of the system.

    As the demographics of drug suppliers have changed, it is becoming harder for the respective regulatory bodies to keep up with the companies around the globe. This has the potential of less than quality products being distributed. We have seen this recently through ever increasing citations. Besides regulatory bodies creating barriers or banning the products from these suppliers not much can be done, as people need drugs.

    As stated earlier regulatory noncompliance issues are an indication of lack of command of the process. Focus is to fix the paper work expecting everything would come in compliance. These are short-term measures and issues will come up again. Instead of fixing the root cause of the problems by having the best process i.e. process centricity; focus is on how to comply with regulations so the product is on the market as quickly as possible.

    Permanent process fixes are needed to produce products that meet or exceed regulations. For it to happen, the current model and practices need to be re-evaluated. This is not on the agenda of many companies. Unless “process centricity” is implemented, supply chain practices and manufacturing model is re-evaluated, we will not see significant changes.

    Some might consider re-evaluation of the current model indication of impending doom because they might have to invest in necessary upgrades. All this might sound negative, but within this negativity are opportunities that are well articulated1, as “You don’t want to let the perennial Voice of Doom kill every project. But if you listen carefully to the Voice of Doom, you’ll find he’s giving you something extremely useful: a list of almost everything that can possibly go wrong with your plan. Think of the VOD “new acronym” as your defensive coordinator, identifying all the holes you need to plug, and backup plans you need to have in place, before you launch. Instead of ostracizing your Doctor No’s and asking them to kindly shut up, why not give them a designated role on the team, telling you what’s likely to go wrong, and then pointing out when it is?”

    Regulatory bodies are trying to coax pharma companies to innovate. However, companies are challenged even to implement minimal regulations we have. Opportunities to serve the needs of billions of the global population who at present do not have access to medicines exist. Unless companies make a move from within, not much will change2. If incorporated, healthcare costs will be lowered and profits will improve, a win-win.

    Pharma’s Path to QbD
    For pharma to incorporate QbD in its operations, it has to separate API manufacturing and their formulations (dose) as two distinct modules. Quality by Design “QbD” is nothing magical but a “repeated practice” of best manufacturing technologies and methods in the manufacture of the active ingredients and their formulation to a dose. Practice of fitting square plug in a round hole3 has to go away. Pharma has to consider and evaluate the associated equipment, unit processes and unit operations to determine if they are the most economic for the products. Unless these considerations are thoroughly reviewed, appropriately incorporated and the manufacturing focus is placed on “process centricity” everyone’s focus is going to stay with “regulation centricity” which is placing “cart before the horse” rather than doing the right thing i.e. “horse before the cart”. We have had cart before the horse for the last fifty plus years. Regulatory bodies have assured only quality drugs are marketed. Some still slip through. In pharmaceutical business winning on product quality is a must otherwise patients die. However, the winning has been due to QbA i.e. trial and error. In spite of documentation, meeting or exceeding specifications can be a hit or miss and it drains profits.

    Significant confusion is created when people discuss drug discovery, its functionality and dose manufacturing (combination of active manufacture and their formulation) in the same sentence. In these discussions new drugs take precedence and everything else is forgotten. Key elements of quality having robust manufacturing processes are never discussed because they are not understood. Manufacture of each API and its formulation has distinct set of expectation. Thus they should be kept separate.

    My emphasis is on the drug manufacturing, a very critical and important stepchild that has to produce drugs of approved performance and quality specifications. To produce drugs of consistent and repeatable quality, one has to understand the nuances of how the molecules are manufactured and formulated efficiently. I might sound repeating myself but unless we can create and practice best manufacturing methods, companies will be slave of regulations rather than master of regulations, as is the case now. 

    Along with the review of existing practices, if we dissect and separate the Brand/ethical from generic drugs, we can easily see how to incorporate methods to produce quality products meeting their purity and performance, which I call is QbD. One fact will remain in either case and that is “unless process centric practices and methods are incorporated from inception, pharmaceuticals will not move away from “quality by analysis” to produce consistent and repeatable quality products i.e. QbD”. “Regulation centricity” and QbA are the cause of the current status. There is an explanation for this reality. Changes needed to incorporate QbD for the existing products are too expensive, time consuming and do not justify investment in the current manufacturing model. Regulations are an impediment also.

    QbD based practices have to start from the day a new drug molecule is conceptualized, continued from bench top to commercial plant through its entire life even if the product becomes generic. Anything short is not worth the attempt. Even if the existing regulations are modified, incorporation of process improvements that will deliver QbD based products due to short patent life, could be difficult to justify for the brand/ethical products. Generic companies might embrace improvements easily but to incorporate “process centricity” significant business model re-configuration5 is necessary.

    It would not surprise me if we hear “it cannot be done” about what has been suggested. Saying “No” to change is normal. It is the first sign of recognition that something better exists.

    With potential savings4 of about 20-25% of the global revenue such a review is necessary. This would result in improved profits and lower healthcare costs and is worth the effort. It will be a very big global win. Downside of such an effort is that it might drive some companies out of business. Fittest will flourish.

    Nothing comes easy, but the opportunity to add an additional two to three billion patients to the customer base is seldom afforded to any business.  It’s well worth the effort. 

    References
    1. McArdle, Megan: Why Negativity Is Really Awesome Business Week, accessed March 3, 2014
    2. Malhotra, Girish: Reading the Tea Leaves: Predictions for Pharma’s Future, www.pharmaevolution.com, January 15, 2014
    3. Malhotra, Girish: Square Plug In A Round Hole: Does This Scenario Exist in Pharmaceuticals? Profitability through Simplicity, August 10, 2010
    4. Malhotra, Girish: Are The Savings of $120-$150 Billions Worth Having? Profitability through Simplicity August 30, 2012
    5. Malhotra, Girish: Financial Justification for QbD and Cost of Regulation Compliance, Profitability through Simplicity, May 22, 2012

    Girish Malhotra
    EPCOT International

    Girish Malhotra, President and founder of Epcot International, has over 43 years of industrial experience in pharmaceuticals; specialty, custom, and fine chemicals; as well as coatings, resins and polymers, and additives. His expertise ranges from manufacturing to process and technology development and business development.
    Related Searches
    • API
    • Development
    • Manufacturing
    • api manufacturing

    Related Pharma Beat

    • Drug Development | Drug Discovery
      Tackling TB Resistance

      Tackling TB Resistance

      The TB Alliance is partnering with universities, government agencies, public agencies and a small number of pharma compani
      Adele Graham-King, Contributing Editor 05.09.17

    • Drug Development | Drug Discovery | R&D

      Is Nicotine Such a ‘Bad Boy’?

      Investigating this controversial compound’s potential health benefits
      Adele Graham-King, Contributing Editor 11.09.16

    • Drug Development | Drug Discovery | R&D

      Blackberry Wine: Could it Help Your Diabetes?

      Recent research points towards the positive impact ‘berry wine’ might have on diabetes
      Adele Graham-King, Contributing Editor 10.11.16


    • Chemistry | Drug Development
      Anyone Fancy a Beer?

      Anyone Fancy a Beer?

      The centuries-old brew continues to be investigated for its medicinal properties
      Adele Graham-King, Contributing Editor 05.05.16

    • Clinical Trials | Drug Development | Drug Discovery | R&D

      Are We There Yet?

      Many promising cancer treatments are on the horizon
      Adele Graham-King, Contributing Editor 07.14.15

    • APIs | Bioassay Development | Clinical Trials | Drug Development | Drug Discovery | Methods Development | Process Development | R&D | Toxicology

      Experimental Drugs

      To use or not to use unlicensed drugs? That is the question.
      Adele Graham-King, Contributing Editor 01.29.15


    • Drug Discovery

      Under the Sea: The Search for New Cures in the “Post-Antibiotic” Era

      A new WHO report raises some frightening questions on antimicrobial resistance, while Scotland’s PharmaSea Project looks for answers in the oceans’ depths
      Adele Graham-King 07.21.14

    • APIs | Chemistry | Drug Development | Inspections | Supply Chain

      API Sourcing

      What factors dictate the migration to China?
      Ed Silverman 01.22.10

    Trending
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • ANI Acquires Branded Products Portfolio From Sandoz
    • Ascendia Pharmaceuticals Poised For Expansion
    • FDA Accepts Airway Therapeutics’ IND For COVID Treatment
    • Sanofi Invests In Cutting Edge Vax Production Site In Singapore
    Breaking News
    • Lonza Expands PyroTec PRO for Endotoxin Testing
    • FDA Accepts Airway Therapeutics’ IND for COVID Treatment
    • Sanofi Invests in Cutting Edge Vax Production Site in Singapore
    • Lilly Modifies Purchase Agreement with U.S. for COVID Therapies
    • Sanofi Acquires Tidal Therapeutics
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Throne Healthtech and PreCon Health, Inc. to Launch Supplements for Pre-, Post-Impact Brain Health
    Green Leafy Vegetable Intervention Reduces Marker of Colorectal Cancer Risk, Study Finds
    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    Coatings World

    Latest Breaking News From Coatings World

    BCF's Tom Bowtell Voted VP of World Coatings Council
    Chromaflo Technologies to Sponsor, Exhibit at North American Pultrusion Conference 2021
    EU Innovation Fund Evaluating Perstorp-created Project AIR
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Avantor to Acquire Ritter GmbH and Affiliates for $1B
    ZOLL Buys Sleep Apnea Device Maker Respicardia
    Digital Diabetes Management Market Projected to Reach $54 Billion by 2027
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Lonza Expands PyroTec PRO for Endotoxin Testing
    FDA Accepts Airway Therapeutics’ IND for COVID Treatment
    Sanofi Invests in Cutting Edge Vax Production Site in Singapore
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    China Builds ‘Beauty and Healthcare Industrial Park’ in Guangzhou
    Edition Spéciale by Luxe Pack is Postponed
    Alexandra Trower Announces Retirement from The Estée Lauder Companies
    Happi

    Latest Breaking News From Happi

    Skin Care Brand Erno Laszlo Appoints General Manager
    Elemis London Arrives at Bloomingdale’s
    Courtin-Clarins Family Invests in Pai Skincare
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Label Traxx launches Siteline online artwork approvals system
    Kocher + Beck appoints new regional sales manager
    Dantex elevates Joseph Sanchez to digital business development manager
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    NXTNano Adding Three Lines
    Honest Company Plans IPO
    Asia Wipes Summit Held Successfully in Shanghai
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    SynerFuse, Cirtec Medical Partner to Develop Back Pain Management Device
    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    NREL: 10 Teams Emerge Victorious in Round 4 of American-Made Solar Prize
    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login